Michael Graham

Michael Graham, MD PhD has been a leader in nuclear medicine and radiopharmaceuticals for over 30 years. Dr. Graham is a Professor of Radiology at the University of Iowa; a former President of the Society of Nuclear Medicine; and a current Co-Chair of the SNMMI Clinical Trials Network, which is an SNMMI entity that has been specifically formed to assist early-stage companies in accelerating new radiopharmaceuticals through clinical stages of development. Dr. Graham has been a Principal Investigator on multiple IND filings and has recently provided leadership in securing an NDA for gallium-68 DOTATOC for imaging of neuroendocrine tumors through his efforts at the Clinical Trials Network. Dr. Graham earned a BS in Engineering from Massachusetts Institute of Technology; a PhD from University of California, Berkeley; and an MD from the University of California San Francisco. He served as Head of Nuclear Medicine at the University of Iowa for over a decade and is a world-renown content expert in image-guided radionuclide therapy for cancer and clinical trial design for this application.